LOS ANGELES – Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine, and other UCLA institutions are presenting data and research findings at the American Society of Clinical Oncology’s annual meeting in Chicago June 3-7, 2022.
Here are some of the abstracts and presentations scheduled, listed by session type, session title, and first author from UCLA:
EDUCATION SESSION
Predictors and Real-World Utilization of Prostate-Specific Radioligand Therapy: PSMA and Beyond
Jeremie Calais, MD, MSc, “Predictive Models for PSMA-Based Radioligand Therapy in Prostate Cancer.” .
ORAL ABSTRACT SESSIONS
Breast cancer
Richard S. Finn, MD, “Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.” .
Genitourinary Cancer – Kidney and Bladder
Karim Chamie, MD, Department of Urology. “Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).” .
Publication Only
Lung Cancer
Kathleen L. Ruchalski, MD, Department of Radiological Sciences. “Inter-reader reliability of immune-specific response criteria (irRECIST & iRECIST).” Info.
Health Services Research Quality and Improvement
Maria Garcia-Jimenez, MD, MHS, “Medical oncologists' perspectives of end-of-life care communication with racial/ethnic minority and limited English proficiency patients.” .
Symptoms and Survivorship
Tina Qing Huang, “Change in breast cancer risk perception related to perceived COVID-19 risk: A WISDOM sub-population analysis.” .
Head and Neck Cancer
Mykola Onyshchenko, MD, PhD, Harbor-UCLA Medical Center. “Clinical utility of circulating tumor DNA in patients with head and neck cancers.” .
POSTER SESSION
Prostate Cancer
Andrei Gafita, MD, “Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP): An international multicenter study.” .
Health Services Research and Quality Improvement
Maria A. Velez, MD, “Cost of consent document (CD) translation is a potential barrier to consenting limited English-proficient participants (LEPPs) in non-industry–sponsored studies (NISS).” .
Lung Cancer
Velez, “Circulating tumor DNA (ctDNA) mutations associate with response in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib (TALA) and temozolomide (TMZ).” .
Gastrointestinal Cancer—Gastroesophageal, Pancreatic and Hepatobiliary
Zev A. Wainberg, MD, “Trial in progress: Phase 1b/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus mFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102).” .
Sarcoma
Noah C. Federman, MD, “A phase 1 dose-escalation/expansion clinical trial of mocetinostat in combination with vinorelbine in adolescents and young adults with refractory and/or recurrent rhabdomyosarcoma: Interim results.” .
Genitourinary Cancer—Prostate, Testicular and Penile
Loic Djaileb, MD, PhD, UCLA Ahmanson Translational Theranostics Division. “Predictive value of extra-prostatic disease detection by pre-operative PSMA-PET for biochemical recurrence-free survival in patients treated with radical prostatectomy: Follow-up analysis of a multicenter prospective phase 3 imaging trial.” .
Lung Cancer—Non-Small Cell Metastatic
Aaron E. Lisberg, MD, Department of Medicine. “Immunogenicity and disease control induced by a multineoantigen vaccine (ADXS-503) in patients with metastatic non–small cell lung cancer who have progressed on pembrolizumab.” .
Lisberg, “Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.” .
Edward B. Garon, MD, MS, “EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC).” .
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Jay M. Lee, MD, “Neoadjuvant and adjuvant capmatinib in resectable non–small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial.” .
Developmental Therapeutics—Immunotherapy
Sarah M. Larson, MD, “CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.” .
Lee S. Rosen, MD, “UCLA Division of Hematology-Oncology, FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro).” .
Daniel S. Shin, MD, PhD, “Enhanced tumor control with a combination of APG-157 and immune checkpoint inhibitors for head and neck cancer.” .
Breast Cancer—Local/Regional/Adjuvant
Sara A. Hurvitz, MD, Department of Medicine, Division of Hematology/Oncology. “TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.”
Symptoms and Survivorship
John A. Glaspy, MD, MPH, “Open-label, phase 2 study of roxadustat for treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies.” .
Central Nervous System Tumors
Vicki Liu, “Characterizing malignant transformation in patients with IDH-mutant glioma.” .
Timothy Francis Cloughesy, “GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.” .
Ethan Wetzel, “A single-institution, retrospective examination of new contrast enhancement, progression, and pseudoprogression in IDH mutant glioma.” .
Prevention, Risk Reduction and Hereditary Cancer
Arya Aliabadi, “Increase in postmenopausal women with distant stage breast cancer in the United States over the last 18 years: Who is the most at risk?” .
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes and Allotransplant
Sara Sakowitz, “Association of frailty with clinical and financial outcomes of allogeneic hematopoietic stem cell transplant.” .
Gastrointestinal Cancer—Colorectal and Anal
J. Randolph Hecht, MD, “Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE).” .
